We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Effect of Caffeine on Ischemic Preconditioning

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00184912
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : November 29, 2006
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by:
Radboud University

September 12, 2005
September 16, 2005
November 29, 2006
September 2003
Not Provided
Percentual difference in Annexin A5 targetting between the experimental and control arm one and four hours after intravenous injection.
Same as current
Complete list of historical versions of study NCT00184912 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
The Effect of Caffeine on Ischemic Preconditioning
Caffeine Reduces Acute Ischemic Preconditioning

Ischaemic preconditioning (IP) describes the phenomenon that brief periods of ischaemia render the (myocardial) muscle more resistant to a subsequent more prolonged period of ischaemia and reperfusion. Animal studies have provided evidence that adenosine receptor stimulation is an important mediator of IP. As caffeine is an effective adenosine receptor antagonist already at concentrations reached after regular coffee consumption, we aimed to assess whether caffeine impairs IP in humans in vivo. We used a novel and well-validated model to study IP in humans: 99m-Tc-annexin A5 scintigraphy in forearm skeletal muscle.

24 healthy volunteers were randomly assigned to either caffeine (4 mg/kg/iv in 10 minutes) or saline before a protocol for IP.

Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
  • Caffeine
  • Ischemic Preconditioning
  • Ischemia-Reperfusion Injury
  • Drug: caffeine
  • Drug: Technetium-TC99m-labeled Annexin A5
  • Procedure: ten minutes forearm ischemia
  • Procedure: ischemic forearm exercise
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
January 2006
Not Provided

Inclusion Criteria:

  • healthy male volunteers

Exclusion Criteria:

Sexes Eligible for Study: Male
18 Years to 50 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Radboud University
ZonMw: The Netherlands Organisation for Health Research and Development
Principal Investigator: Gerard Rongen, MD, Phd Radboud University Nijmegen Medical Centre / Department of pharmacology and Toxicology
Radboud University
February 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP